Novo Nordisk has a price fix solution for uninsured patients with diabetes, but not for HSA holders or people with normal ...

Novo Nordisk’s (NYSE:NVO) top executive faced a U.S. Senate grilling on Tuesday over the high prices of the company’s weight loss drug Wegovy and diabetes treatment Ozempic, as demand for both ...

U.S. Sen. Bernie Sanders said major PBMs have agreed not to limit coverage of Ozempic and Wegovy if Novo lowers its prices.

DexCom ( DXCM -1.08%) is not a stock that investors should be rushing to sell. It has a few different opportunities to ...

Novo Nordisk's top executive faced a Senate grilling on Tuesday over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic, as demand for both injections soars in the ...

Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

The Vermont independent says he has secured pledges from the major PBMs that they would not limit coverage of Ozempic and Wegovy if the company lowers its list prices — an announcement that CEO Lars ...

Amgen's immunology drug results —The Novo Nordisk Senate hearing —Sanofi's soul-searching Read on to learn more.

Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...

While several factors predict sustained glycemic control, predictors of sustained weight control with tirzepatide appear ...